TheProfitWatch

AKRO - Akero Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
53.8 -0.21 (-0.39%) --- 0.0 (0.0%) -0.01 (-0.02%) 0.05 (0.09%) -0.23 (-0.43%) -0.01 (-0.02%) -0.01 (-0.02%)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
-0.86
Diluted EPS:
-0.86
Basic P/E:
-62.314
Diluted P/E:
-62.314
RSI(14) 1m:
0.0
VWAP:
53.59
RVol:
0.9699

Events

Period Kind Movement Occurred At

Related News